CA

Cardiogeni Plc

Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BTBLFC12
LEI:
9845000F8F59ATZD8F92
Country:
United Kingdom
Address:
Celixir House Stratford-Upon-Avon Business & Technology Park, CV37 7GZ Stratford-Upon-Avon
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Cardiogeni Plc is a clinical-stage biotechnology company, founded by Nobel Laureate Professor Sir Martin Evans, that focuses on developing next-generation treatments for heart failure. The company specializes in regenerative medicine, utilizing a proprietary platform technology to create engineered cellular medicines. These therapies are designed to treat patients with heart failure, particularly those undergoing coronary artery bypass surgery. Cardiogeni's lead product candidate is CLXR-001. The company's mission is to become a market leader in heart failure regeneration by developing a new class of life-saving treatments.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Cardiogeni Plc. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-24 17:45
Share Issue/Capital Change
Details of Advanced Subscription & Company Update
English 21.0 KB
2025-07-24 08:00
Capital/Financing Update
£150,000 Advanced Subscription Agreement
English 14.2 KB
2025-07-02 08:00
Regulatory News Service
Appointment of corporate broker
English 11.6 KB

Automate Your Workflow. Get a real-time feed of all Cardiogeni Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Cardiogeni Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Cantargia Logo
Develops antibody-based drugs targeting IL1RAP for cancer and inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Develops TPD drugs for oncology and autoimmune disorders, targeting 'undruggable' proteins.
Poland CTX
Cellectis Logo
Biopharma using gene-editing to create off-the-shelf CAR T-cell cancer therapies.
France ALCLS
Celyad Oncology SA Logo
Clinical-stage biotech developing allogeneic & autologous CAR T-cell therapies for cancer.
Belgium CYAD
Cereno Scientific AB Logo
Clinical-stage biotech developing treatments for rare cardiovascular & pulmonary diseases.
Sweden CRNO
Ceres Power Holdings PLC Logo
Licensing solid oxide tech (SOFC/SOEC) for clean power and green hydrogen to global partners.
United Kingdom CWR
Cessatech A/S Logo
Develops non-invasive pain relief, like a nasal spray, for children.
Denmark CESSA
CHOSA Oncology AB Logo
Develops diagnostics and drug delivery for personalized cancer therapy.
Sweden CHOSA
Cinclus Pharma Holding AB Logo
Late-stage pharma developing a next-gen P-CAB drug for severe GERD and H. pylori.
Sweden CINPHA
Circio Holding ASA Logo
Developing circular RNA medicines for gene and cell therapies for hard-to-treat diseases.
Norway CRNA